Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Summary

In adults with suboptimal weight loss after bariatric surgery, weekly semaglutide 2.4 mg plus lifestyle counseling produced a mean 18.0% weight loss over 68 weeks versus 0.4% with placebo, for an adjusted difference of −19.18% (P<0.001). Safety aligned with the known profile, with no new concerns in post-bariatric patients and improvements in metabolic parameters and quality of life.

Key Findings

• Semaglutide 2.4 mg led to −18.0% mean weight loss at 68 weeks versus +0.4% with placebo; adjusted difference −19.18% (95% CI −23.4 to −14.8; P<0.001).
• Metabolic parameters and quality of life improved more with semaglutide than placebo.
• Safety profile matched known GLP1R agonist effects; no new safety signals in post-bariatric patients (8 serious AEs, 1 SUSAR, no treatment-related deaths).

Clinical Implications

Semaglutide 2.4 mg can be considered as a first-line pharmacologic option for patients with inadequate weight loss after bariatric surgery, with monitoring for known gastrointestinal adverse events.

Limitations

• Modest sample size (n=70 randomized) limits precision and subgroup analyses.
• Post-bariatric population may limit generalizability to other obesity phenotypes.

Future Directions

Head-to-head comparisons with other anti-obesity pharmacotherapies, durability and maintenance strategies post-treatment, and cost-effectiveness analyses in post-bariatric care pathways.